Stage IV Renal Cell Cancer AJCC v7
20
0
6
9
Key Insights
Highlights
Success Rate
64% trial completion
Published Results
13 trials with published results (65%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
25.0%
5 terminated out of 20 trials
64.3%
-22.2% vs benchmark
10%
2 trials in Phase 3/4
144%
13 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (20)
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer